Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 5/20 | 0.52 |
| ▸ | MAOA | P21397 | 4/20 | 0.52 |
| ▸ | CA12 | O43570 | 3/20 | 0.49 |
| ▸ | CA1 | P00915 | 3/20 | 0.49 |
| ▸ | CA2 | P00918 | 3/20 | 0.49 |
| ▸ | CA9 | Q16790 | 3/20 | 0.49 |
| ▸ | MAOB | P27338 | 2/20 | 0.49 |
| ▸ | MIF | P14174 | 3/20 | 0.45 |
| ▸ | DDX3X | O00571 | 4/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | CD74 | P04233 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21157740 | 0.87 | NOTUM (0.57) | NOTUMCA12CA1CA2CA9 | |
| SCHEMBL21156932 | 0.86 | NOTUM (0.50) | NOTUMCA12CA1CA2CA9 | |
| SCHEMBL21156875 | 0.86 | MIF (0.60) | CA12CA1CA2CA9MIF | |
| SCHEMBL21156929 | 0.86 | MIF (0.50) | NOTUMCA1CA2CA9MIF | |
| SCHEMBL15060892 | 0.85 | MIF (0.62) | NOTUMMAOACA12CA1CA2 | |
| SCHEMBL21157760 | 0.85 | NOTUM (0.51) | NOTUMMIFDDX3XCD74 | |
| SCHEMBL21156454 | 0.85 | DDX3X (0.45) | NOTUMMIFDDX3XBCHECD74 | |
| SCHEMBL21156928 | 0.85 | MIF (0.52) | NOTUMCA12CA1CA2CA9 | |
| SCHEMBL13527252 | 0.84 | MIF (0.60) | NOTUMMAOACA12CA1CA2 | |
| SCHEMBL21157743 | 0.82 | BCHE (0.42) | NOTUMCA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190211046-A1 | TRIAZOLE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | BioVersys AG (CH) | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190211046-A1 | TRIAZOLE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | PROKR1, ARG1, ARG2 | NOTUM 3719/4885MAOA 2033/4885CA12 4447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.